scholarly journals Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development

Drug Safety ◽  
2018 ◽  
Vol 42 (3) ◽  
pp. 453-461 ◽  
Author(s):  
Nadezda Abramova ◽  
Julie Hubbard ◽  
Joan Schertz ◽  
Emilia Richter
Keyword(s):  
Follicular Development ◽  
Follitropin Alfa ◽  
Stimulation Of

AUGMENTATION BY CHLORMADINONE OF THE UTERINE WEIGHT RESPONSE TO HUMAN CHORIONIC GONADOTROPHIN IN INTACT IMMATURE RATS

1965 ◽  
Vol 33 (3) ◽  
pp. 447-454
Author(s):  
M. J. K. HARPER
Keyword(s):  
Single Injection ◽  
Direct Action ◽  
Follicular Development ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Female Rats ◽  
Uterine Weight ◽  
Control Value ◽  
Orally Active ◽  
Stimulation Of

SUMMARY Administration of chlormadinone, an orally active progestational agent without significant oestrogenic activity, to intact immature female rats did not affect either ovarian or uterine weight significantly compared with controls. A single injection of human chorionic gonadotrophin (HCG) caused a 73 % increase in uterine weight in 24 hr. over the control value. This dose significantly increased ovarian weight and although it caused some stimulation of follicular development, ovulation during this time did not occur. When animals were treated with chlormadinone for 8 days, and received HCG on the 8th day, uterine weight was 170% greater than in the controls and 56% greater than with HCG alone. The uterine weight produced was similar to that found in animals treated with mestranol, a potent oestrogen, and HCG. In ovariectomized animals HCG did not affect uterine weight, while the small increase produced by chlormadinone was unaltered when HCG also was given. Mechanisms are discussed by which this augmentation of the uterine response to HCG might be produced. It seems most likely that chlormadinone administration causes storage of endogenous gonadotrophin in the pituitary, and that the exogenous gonadotrophin acts as the 'trigger' for the release of stored hormone, probably by a direct action on the hypothalamus.

scholarly journals Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization

2020 ◽  
Vol 13 (7) ◽  
pp. 136
Author(s):  
Loredana Bergandi ◽  
Stefano Canosa ◽  
Andrea Roberto Carosso ◽  
Carlotta Paschero ◽  
Gianluca Gennarelli ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
In Vitro Fertilization ◽  
Ovarian Stimulation ◽  
Controlled Ovarian Stimulation ◽  
Vitro Fertilization ◽  
Follitropin Alfa ◽  
Extraction And Purification ◽  
Recombinant Technology ◽  
Stimulation Of

Exogenous human follicle-stimulating hormone (hFSH), either derived from extraction and purification from the urine or obtained by recombinant technology in the form of follitropin α, β and δ (rFSH), has been used for decades in the treatment of infertility. The main applications of FSH treatment in the woman have been, and still are, ovulation induction in oligo-anovulatory subjects, and stimulation of the development of a cohort of follicles in patients undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF). In the last years, two biosimilars of follitropin alfa, rFSH compounds structurally and functionally similar to the originator, have been approved and marketed for clinical use in Europe. Moreover, some other rFSH biosimilars are currently under investigation. The objective of this article is to review the available evidences comparing the efficacy, safety, and cost-effectiveness of rFSH follitropin alpha originator with its biosimilars, discussing the clinical trials that allowed biosimilars to get registration and marketing authorization.

Ovarian response patterns to human menopausal gonadotropin in mixed hyperandrogenemia

1990 ◽  
Vol 123 (6) ◽  
pp. 598-602
Author(s):  
Miklos Hamori ◽  
Attila Török ◽  
Manfred Zwirner ◽  
Hans-Rudolf Tinneberg
Keyword(s):  
Follicular Development ◽  
Ovarian Response ◽  
Human Menopausal Gonadotropin ◽  
Response Patterns ◽  
Polycystic Ovaries ◽  
Ovarian Volume ◽  
Wide Range ◽  
Suppression Test ◽  
Dexamethasone Suppression ◽  
Stimulation Of

Abstract. Twenty-eight hyperandrogenemic women suffering from infertility owing to chronic anovulation were treated with hMG. Only 7 patients exhibited the typical polycystic ovarian appearance of multiple subcortical cysts, however, a wide range (6-15 cm3) of ovarian volume was observed. The LH/FSH ratio was consistently lower than 2.5 and circulating androgens of both ovarian and adrenal origin were elevated. The 4 days dexamethasone suppression test showed more than 80% suppression of dehydroepiandrosterone-sulphate and a variable (40-60%) reduction of testosterone and androstenedione levels. Two different patterns of follicular development were observed in response to hMG. Sixteen patients exhibited polycystic ovarian reaction, whereas 12 women had a follicular growth pattern similar to that seen in hMG-stimulated normo-ovulatory subjects. Patients with polycystic ovarian reaction showed a significantly increased androstenedione response to hMG when compared with the other group. Moreover, the non-stimulated ovarian volume was found to be markedly greater than in subjects without polycystic reaction. Thus, ovarian stimulation of patients with mixed hyperandrogenemia may elucidate the presence of borderline polycystic ovaries; furthermore the increased accumulation of androstenedione may suggest an inherent ovarian failure.

scholarly journals 175. EFFECTS OF SPECIES DIFFERENCES ON OOCYTE REGULATION OF GRANULOSA CELL PROLIFERATION

2010 ◽  
Vol 22 (9) ◽  
pp. 93
Author(s):  
J. Lin ◽  
J. Juengel ◽  
K. McNatty
Keyword(s):  
Follicular Development ◽  
Cumulus Cells ◽  
Molecular Forms ◽  
Thymidine Uptake ◽  
Mature Form ◽  
Reducing Conditions ◽  
Morphogenetic Protein ◽  
Growth Differentiation Factor 9 ◽  
Stimulation Of

The role of oocytes in regulating ovulation quota between species is not fully understood. In sheep, the oocyte-derived growth factors, growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) have profound effects on ovarian follicular development and ovulation-quota. The aim of these studies was to compare the ability of oocytes from sheep (low ovulation-rate) and rat (poly-ovulator) to stimulate radiolabelled thymidine uptake by granulosa cells (GC) both within and between the two species. For these experiments, 32 oocytes denuded of cumulus-cells were co-incubated with 20 000 GC from either species. Rat or sheep oocytes stimulated thymidine uptake by GC from the same species (P < 0.005). Sheep oocytes also stimulated thymidine uptake by rat GC (P < 0.001) but not vice versa. To investigate this further, oocytes and GC were co-incubated with 3.2 µg/mL or 7.6 mg/mL monoclonal antibodies specific to GDF9 or BMP15 respectively and to a hydatids antigen (control). Both sheep and rat oocyte stimulation of thymidine uptake by GC was inhibited with the GDF9 antibody (P < 0.05) but not control, irrespective of species of GC. Sheep oocyte stimulation of rat GC was also inhibited using an antibody to BMP15 (P < 0.05). However, when using the BMP15 antibody to block the effects of rat oocytes on rat GC, the inhibition of thymidine uptake was modest (i.e. ~10%) albeit significant (P < 0.05). The molecular forms of GDF9 and BMP15 in spent media were examined by Western blotting under reducing conditions. For both species, oocyte-secreted GDF9 was present in the mature form. For sheep oocytes, secreted BMP15 was present as promature and monomeric mature forms whereas from rats, trace amounts of mature form was sometimes, but not always, detected. Thus, in sheep both BMP15 and GDF9 are essential for regulating GC proliferation whereas in rats, although responsive to BMP15, GC proliferation is likely regulated primarily by GDF9.

Sign in / Sign up

Export Citation Format

Share Document